BACKGROUND: Proton pump inhibitors (PPIs) are unstable at a low PH. Accelerated transfer of PPIs to the upper small intestine may influence the pharmacokinetics of PPIs. AIM: To see if concomitant use of mosapride citrate with rabeprazole sodium influences the pharmacokinetics of the PPI. METHODS: Two-way crossover pharmacokinetic studies were conducted in 9 healthy subjects. 20 mg of rabeprazole was given orally and plasma was obtained before and 1, 2, 3, 4, 5, 6 and 8 h after the dosing. Two weeks later, 5 mg of mosapride was given concomitantly with rabeprazole and plasma was collected as above. The plasma concentrations of rabeprazole were determined by high-performance liquid chromatography. The maximum plasma concentrations (C(max)) and the area under the time-plasma concentration curve (AUC) of rabeprazole, and the time to maximum plasma concentration (t(max)) were compared in the presence or absence of mosapride. RESULTS: Concomitant use of mosapride resulted in significant increases of mean C(max) and mean AUC with ratios of 1.57 and 1.47, respectively. The median t(max) changed from 4 to 3 h, although the change was not significant. CONCLUSIONS: Mosapride significantly influenced pharmacokinetics of rabeprazole. Co-administration of mosapride could have some favorable effect in PPIs-based therapy. Copyright 2008 S. Karger AG, Basel.
BACKGROUND: Proton pump inhibitors (PPIs) are unstable at a low PH. Accelerated transfer of PPIs to the upper small intestine may influence the pharmacokinetics of PPIs. AIM: To see if concomitant use of mosapride citrate with rabeprazole sodium influences the pharmacokinetics of the PPI. METHODS: Two-way crossover pharmacokinetic studies were conducted in 9 healthy subjects. 20 mg of rabeprazole was given orally and plasma was obtained before and 1, 2, 3, 4, 5, 6 and 8 h after the dosing. Two weeks later, 5 mg of mosapride was given concomitantly with rabeprazole and plasma was collected as above. The plasma concentrations of rabeprazole were determined by high-performance liquid chromatography. The maximum plasma concentrations (C(max)) and the area under the time-plasma concentration curve (AUC) of rabeprazole, and the time to maximum plasma concentration (t(max)) were compared in the presence or absence of mosapride. RESULTS: Concomitant use of mosapride resulted in significant increases of mean C(max) and mean AUC with ratios of 1.57 and 1.47, respectively. The median t(max) changed from 4 to 3 h, although the change was not significant. CONCLUSIONS:Mosapride significantly influenced pharmacokinetics of rabeprazole. Co-administration of mosapride could have some favorable effect in PPIs-based therapy. Copyright 2008 S. Karger AG, Basel.